Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases
NCT05564221Phase 1Completed
- Sponsor
- Yuhan
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YH35324 in atopic dermatitis (AD) and allergic disease (3 arms), sponsored by Yuhan. Primary endpoint: Occurrence and severity of adverse events at 141 days. Started Nov 2022; status: completed.
02
Drugs
YH35324
03
Conditions
atopic dermatitis (AD)allergic disease
Beyond the preview
Go deeper on NCT05564221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564221.